COMMENTARY

Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications

April 27, 2015
The launch of Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) last September has changed the landscape of malignant melanoma treatments in Japan. Before, patients with metastatic malignant melanoma could use Kyowa Hakko Kirin’s anticancer drug dacarbazine, but patients who could not…

To read the full story

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…